The Application of Haishi EEG Biofeedback in Post-stroke Insomnia (PSI)
Wang Huanqun,
Zou Weiwu,
Gan Ting
Issue:
Volume 6, Issue 1, March 2022
Pages:
1-7
Received:
29 December 2021
Accepted:
15 January 2022
Published:
24 January 2022
Abstract: [Objective] Selected the Department of Neurology and Rehabilitation, Chongqing Yongchuan Hospital of Traditional Chinese Medicine, from July 2020 to July 2021, inpatients who meet 60 cases of post-stroke insomnia patients, use the insomnia treatment instrument ES-100H EEG biofeedback treatment instrument Two electrodes are placed at the post-auricular mastoid. The treatment intensity: tolerable, 5 times a week, 10 times as a course of treatment. On the basis of conventional treatment, plus EEG biofeedback. In Haishi: Half an hour is selected between 21:00-23:00 for treatment. Compared with the same period last year.[Results] Compared with the same period last year, the improvement in indicators such as the quality of life of patients, mood was significantly better than that of the control group (P<0.05), but it was not statistically significant compared with the control group (P>0.05), in terms of reducing the number of days of hospitalization, Hospital expenses, Frequency of hospitalizations.[Conclusion] 21:00-23:00 (Hai Shi) The use of EEG biofeedback for post-stroke insomnia can significantly improve the symptoms of post-stroke insomnia, which is worthy of promotion. the rational use of medical insurance funds requires multi-channel observation to achieve a win-win situation between hospitals, national medical insurances and patients, control medical expenses, improve hospital management, increase the effectiveness of medical insurance funds, and enhance medical system services.
Abstract: [Objective] Selected the Department of Neurology and Rehabilitation, Chongqing Yongchuan Hospital of Traditional Chinese Medicine, from July 2020 to July 2021, inpatients who meet 60 cases of post-stroke insomnia patients, use the insomnia treatment instrument ES-100H EEG biofeedback treatment instrument Two electrodes are placed at the post-auricu...
Show More
Comparison of Drug-eluting Balloon Versus Drug-eluting Stent in de Novo Coronary Artery Disease: A Systematic Review and Meta-analysis
Cao Mingkun,
Yinyuxia,
Wang Zhiyong,
Zhang Haijun
Issue:
Volume 6, Issue 1, March 2022
Pages:
8-14
Received:
1 September 2021
Accepted:
16 September 2021
Published:
28 January 2022
Abstract: Background: Drug- eluting balloon (DEB) and drug- eluting stent (DES) are widely used in cardiovascular interventional surgery. But the long-term safety of DEB is unclear. Objective: To compare the efficacy and safety of DEB with DES for the treatment of de novo coronary artery disease (CAD). Methods: We conducted a meta-analysis of relevant studies identified in the Pubmed, Embase, and Cochrane Library databases. Random and fixed effects models were used to calculate the relative risks (RR) and standard mean differences (SMD) with 95% confidence intervals. Results: Nine studies in 1946 patients were included in this analysis. There was no significant difference in the primary endpoint of major adverse cardiovascular events (MACE) or in the efficacy endpoint of late lumen loss (LLL) between the DEB and DES groups. For follow-up < 12 months, there was no significant difference between DEB and DES for each MACE component, including target lesion revascularization (TLR), stent thrombosis (ST), myocardial infarction (MI), and death. However, a lower risk for MI and death was observed for DEB when the follow-up time was ≥ 12 months. Conclusion: DEB is equivalent to DES for the treatment of patients with de novo CAD and appears to represent a safer option for long-term treatment of this patient population.
Abstract: Background: Drug- eluting balloon (DEB) and drug- eluting stent (DES) are widely used in cardiovascular interventional surgery. But the long-term safety of DEB is unclear. Objective: To compare the efficacy and safety of DEB with DES for the treatment of de novo coronary artery disease (CAD). Methods: We conducted a meta-analysis of relevant studie...
Show More
The Clinical Research on the Anticancer Action of Si-Miao Yong-An Decoction
He Ya Ping,
Hou Ming Yan,
Wu Yv,
Peng Hai Yan
Issue:
Volume 6, Issue 1, March 2022
Pages:
15-19
Received:
16 January 2022
Accepted:
27 January 2022
Published:
9 February 2022
Abstract: Background: Si-Miao Yong-An Decoction is composed of four herbs: honeysuckle, Radix Sophora, Angelica and Licorice. It has the functions of clearing away heat and detoxification, promoting blood circulation and clearing collaterals. It is a famous ancient formula for the treatment of gangrene, and is now widely used in the treatment of multiple diseases in various systems. Objective: To explore the anticancer action of Si-Miao Yong-An decoction in the clinical application of the treatment of some kinds of malignant tumors. Methods: This paper reviews the sections in classical TCM books and recent report of clinical study of Si-Miao Yong-An Decoction in the treatment of cervical cancer, breast cancer, nasopharyngeal cancer, oral cancer, gastric cancer and etc. Results: The composition of the prescription was first recorded in Shen Yi Mi Zhuan in Han dynasty, and also recorded in the book of Shi Shi Mi Lv and Yan Fang Xin Bian, and it was formally named in Journal of TCM in the year of 1958. It was useful in relieving the clinical symptoms and elevating the life quality besides preventing the recurrence and metastasis of cancer. Conclusion: Si-Miao Yong-An Decoction is effective in treating various malignant tumors and the related complications of the syndrome of blood stasis and heat-toxin. It is promising to provide a new direction for better exploration of traditional Chinese medicine and its application in the treatment of malignant tumors in the future.
Abstract: Background: Si-Miao Yong-An Decoction is composed of four herbs: honeysuckle, Radix Sophora, Angelica and Licorice. It has the functions of clearing away heat and detoxification, promoting blood circulation and clearing collaterals. It is a famous ancient formula for the treatment of gangrene, and is now widely used in the treatment of multiple dis...
Show More
